PL1860101T3 - Sól winianu izofagominy i sposoby zastosowania - Google Patents
Sól winianu izofagominy i sposoby zastosowaniaInfo
- Publication number
- PL1860101T3 PL1860101T3 PL07252109T PL07252109T PL1860101T3 PL 1860101 T3 PL1860101 T3 PL 1860101T3 PL 07252109 T PL07252109 T PL 07252109T PL 07252109 T PL07252109 T PL 07252109T PL 1860101 T3 PL1860101 T3 PL 1860101T3
- Authority
- PL
- Poland
- Prior art keywords
- isofagomine
- tartrate
- sale
- methods
- salt
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Cephalosporin Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US80802006P | 2006-05-24 | 2006-05-24 | |
US89071907P | 2007-02-20 | 2007-02-20 | |
EP07252109A EP1860101B1 (en) | 2006-05-24 | 2007-05-23 | Tartrate sale of isofagomine and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
PL1860101T3 true PL1860101T3 (pl) | 2011-10-31 |
Family
ID=38462442
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL07252109T PL1860101T3 (pl) | 2006-05-24 | 2007-05-23 | Sól winianu izofagominy i sposoby zastosowania |
Country Status (14)
Country | Link |
---|---|
US (2) | US7501439B2 (pl) |
EP (1) | EP1860101B1 (pl) |
JP (1) | JP5292605B2 (pl) |
AT (1) | ATE504570T1 (pl) |
AU (1) | AU2007202359B2 (pl) |
BR (1) | BRPI0706114A2 (pl) |
CA (1) | CA2590122C (pl) |
DE (1) | DE602007013648D1 (pl) |
DK (1) | DK1860101T3 (pl) |
IL (1) | IL183415A (pl) |
MX (1) | MX2007006175A (pl) |
PL (1) | PL1860101T3 (pl) |
PT (1) | PT1860101E (pl) |
WO (1) | WO2007140212A2 (pl) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2006254796B2 (en) | 2005-06-08 | 2012-08-16 | Amicus Therapeutics, Inc. | Treatment of CNS disorders associated with mutations in genes encoding lysosomal enzymes |
BRPI0713442A2 (pt) * | 2006-06-23 | 2012-03-06 | Amicus Therapeutics, Inc. | Método para o tratamento de desrodens neurológicas, pelo aumento da atividade de b-glicocerebrosidase |
KR101597499B1 (ko) * | 2007-05-22 | 2016-02-24 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 이소파고민과 이의 유도체를 제조하는 새로운 방법 |
EP2946785B1 (en) | 2008-02-12 | 2018-10-24 | Amicus Therapeutics, Inc. | Method to predict response to pharmacological chaperone treatment of diseases |
EP2361089A4 (en) * | 2008-11-14 | 2012-08-22 | Parkinson S Inst | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED FUNCTION OF -SYNUCLEINE |
CN102686237B (zh) | 2009-07-28 | 2018-10-19 | 夏尔人类遗传性治疗公司 | 用于治疗戈谢病的组合物 |
PT2995306T (pt) * | 2009-10-19 | 2019-03-29 | Amicus Therapeutics Inc | Novas composições para prevenção e/ou tratamento de disfunções de armazenamento lisossomal |
ES2814178T3 (es) | 2009-10-19 | 2021-03-26 | Amicus Therapeutics Inc | Nuevas composiciones para prevenir y/o tratar trastornos degenerativos del sistema nervioso central |
ES2724531T3 (es) | 2011-05-12 | 2019-09-11 | Proteostasis Therapeutics Inc | Reguladores de proteostasis |
AU2012272815B2 (en) * | 2011-06-22 | 2017-09-07 | The General Hospital Corporation | Treatment of proteinopathies |
JP2015504919A (ja) | 2012-01-25 | 2015-02-16 | プロテオステイシス セラピューティクス,インコーポレイテッド | プロテアソーム活性を調節する化合物 |
CN104519905A (zh) | 2012-03-02 | 2015-04-15 | 夏尔人类遗传性治疗公司 | 用于治疗iii型戈谢病的组合物和方法 |
AU2013240486B2 (en) | 2012-03-27 | 2017-10-26 | Amicus Therapeutics, Inc. | Novel compounds for preventing and/or treating lysosomal storage disorders and/or degenerative disorders of the central nervous system |
JP2015512913A (ja) * | 2012-03-28 | 2015-04-30 | ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ | グルコセレブロシダーゼ活性剤として有用なサリチル酸誘導体 |
EP3318277A1 (en) | 2016-11-04 | 2018-05-09 | Institut du Cerveau et de la Moelle Epiniere-ICM | Inhibitors of glucosylceramide synthase for the treatment of motor neuron diseases |
DE102017103346A1 (de) * | 2017-02-17 | 2018-08-23 | Lts Lohmann Therapie-Systeme Ag | Strukturierte orodispergierbare Filme |
BR112020007820A2 (pt) * | 2017-10-26 | 2020-10-20 | Shire Human Genetic Therapies, Inc. | formulações compreendendo glucocerebrosidase e isofagomina |
CN112585132A (zh) | 2018-06-27 | 2021-03-30 | 蛋白质平衡治疗股份有限公司 | 蛋白酶体活性增强化合物 |
EP3814336A1 (en) | 2018-06-27 | 2021-05-05 | Proteostasis Therapeutics, Inc. | Proteasome activity enhancing compounds |
US20220184185A1 (en) | 2018-07-25 | 2022-06-16 | Modernatx, Inc. | Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders |
JP2022530017A (ja) * | 2019-04-25 | 2022-06-27 | 武田薬品工業株式会社 | イソファゴミン塩、その使用方法および製剤 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5844102A (en) | 1994-07-07 | 1998-12-01 | University Of Maryland Baltimore County | Glycohydrolase inhibitors, their preparation and use thereof |
US6274597B1 (en) * | 1998-06-01 | 2001-08-14 | Mount Sinai School Of Medicine Of New York University | Method of enhancing lysosomal α-Galactosidase A |
-
2007
- 2007-05-23 PT PT07252109T patent/PT1860101E/pt unknown
- 2007-05-23 AT AT07252109T patent/ATE504570T1/de active
- 2007-05-23 WO PCT/US2007/069550 patent/WO2007140212A2/en active Application Filing
- 2007-05-23 DK DK07252109.9T patent/DK1860101T3/da active
- 2007-05-23 EP EP07252109A patent/EP1860101B1/en not_active Not-in-force
- 2007-05-23 MX MX2007006175A patent/MX2007006175A/es active IP Right Grant
- 2007-05-23 PL PL07252109T patent/PL1860101T3/pl unknown
- 2007-05-23 DE DE602007013648T patent/DE602007013648D1/de active Active
- 2007-05-23 US US11/752,658 patent/US7501439B2/en active Active
- 2007-05-24 JP JP2007138358A patent/JP5292605B2/ja not_active Expired - Fee Related
- 2007-05-24 IL IL183415A patent/IL183415A/en active IP Right Grant
- 2007-05-24 AU AU2007202359A patent/AU2007202359B2/en not_active Ceased
- 2007-05-24 BR BRPI0706114-5A patent/BRPI0706114A2/pt not_active Application Discontinuation
- 2007-05-24 CA CA 2590122 patent/CA2590122C/en not_active Expired - Fee Related
-
2009
- 2009-02-23 US US12/391,049 patent/US7863453B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
BRPI0706114A2 (pt) | 2008-11-18 |
US7501439B2 (en) | 2009-03-10 |
AU2007202359B2 (en) | 2012-02-16 |
IL183415A0 (en) | 2007-09-20 |
US7863453B2 (en) | 2011-01-04 |
CA2590122A1 (en) | 2007-11-24 |
PT1860101E (pt) | 2011-07-12 |
EP1860101A1 (en) | 2007-11-28 |
DK1860101T3 (da) | 2011-07-25 |
JP2007314540A (ja) | 2007-12-06 |
MX2007006175A (es) | 2009-02-16 |
US20090176830A1 (en) | 2009-07-09 |
AU2007202359A1 (en) | 2007-12-13 |
WO2007140212A2 (en) | 2007-12-06 |
EP1860101B1 (en) | 2011-04-06 |
US20070281975A1 (en) | 2007-12-06 |
WO2007140212A3 (en) | 2008-12-24 |
IL183415A (en) | 2012-03-29 |
JP5292605B2 (ja) | 2013-09-18 |
CA2590122C (en) | 2015-03-31 |
DE602007013648D1 (de) | 2011-05-19 |
ATE504570T1 (de) | 2011-04-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL1860101T3 (pl) | Sól winianu izofagominy i sposoby zastosowania | |
UA88481C2 (ru) | Донепезила фумарат, пригодный для получения фармацевтических композиций | |
ZA200804030B (en) | Improved process for the preparation of 4-(benzimidazolylmethylamino)benzamides and the salts thereof | |
EA200702208A1 (ru) | Ингибиторы дипептидилпептидазы-iv | |
UA92472C2 (ru) | Фармацевтическая композиция, которая содержит 4-{4-[3-(4-хлор-3-трифторметилфенил)-уреидо]- 3-фторфенокси}-пиридин-2-карбоновой кислоты метиламид (варианты), способ получения твердой дисперсии указанного соединения и способ лечения с применением указанного соединения (варианты) | |
IL210577A (en) | Compound 1,2,3,4-tetrahydrocyclopenta [b] indole-3-yl acetic acid, salt, hydrate and solvent, pharmaceutical, compound, salt, hydrate, solvent or pharmaceutical for use as a medicine or treatment Salt, hydrate, solvent or pharmaceutical preparation in the manufacture of a drug and process for the preparation | |
ATE530519T1 (de) | Cyclobutylaminderivate | |
PL1960379T3 (pl) | Pochodne N-(1-alkilo-2-fenyloetylo)-karboksamidu i ich zastosowanie jako fungicydów | |
WO2005075425A3 (en) | Substituted bisarylurea derivatives as kinase inhibitors | |
EP1934025A4 (en) | COMPOSITION FOR THE TREATMENT OF WOOD, METHOD FOR THE TREATMENT OF WOOD AND WOOD PRODUCT | |
MXPA05012678A (es) | Forma cristalina del agonista del receptor adrenergico beta2. | |
GB0510196D0 (en) | Composition for treatment of a detached retina and method of production thereof | |
NO20081905L (no) | Benzotiazolcyklobutylaminderivater og deres anvendelse som histamin-3-reseptorligander | |
PL1617834T3 (pl) | Kompozycja farmaceutyczna zawierająca mleczan i jej zastosowania | |
BRPI0415164A (pt) | dispositivo para administrar uma composição bioterapêutica, composição bioterapêutica, método de preparação de uma composição bioterapêutica, método de tratamento, e dispensador | |
UA97122C2 (ru) | Кристаллическая форма миндальной кислоты как ингибитор тромбина (варианты) | |
IL186465A0 (en) | Process for preparing levetiracetam and racemization of (r)-and(s)-2-amino butynamide and the corresponding acid derivatives | |
WO2005062992A3 (en) | Substituted melatonin derivatives, process for their preparation, and methods of use | |
WO2010101301A9 (en) | Prophylaxis and treatment of macular degeneration and retinopathy using a prdx protein | |
HUP0500975A2 (en) | Process for producing of extract of sour cherry seed, use of extract for producing of medicament and medicaments consist extract | |
CY1110156T1 (el) | Υποκατεστημενες ενωσεις 4,5,6,7-τετραϋδρο-βενζοθειαζολ-2-υλαμινης | |
DE602007010926D1 (de) | Neues verfahren zur herstellung von ammoniumsalzen von esomeprazol | |
ATE460168T1 (de) | Nicht-radioaktives strontiummittel zur behandlung von krebs | |
PT1720867E (pt) | Processo para a preparação de ziprasidona | |
NO20063617L (no) | Diarylmetylidenpiperidinderivater, fremstilling og anvendelse derav |